Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Neoantigen based dendritic cell therapeutic - Shenzhen Dengding Biopharma

Next Previous
Drug Profile

Neoantigen based dendritic cell therapeutic - Shenzhen Dengding Biopharma

Alternative Names: Neoantigen-based DC immune preparation - Shenzhen Dengding Biopharma; Personalized tumor neoantigen DC therapeutic immune preparation - Shenzhen Dengding Biopharma

Latest Information Update: 28 May 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shenzhen Dengding Biopharma
  • Developer Shenzhen Dengding Biopharma; The First Affiliated Hospital of Nanchang University
  • Class Antineoplastics; Cell therapies; Immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 28 May 2026 No recent reports of development identified for clinical-Phase-Unknown development in Solid-tumours(Inoperable/Unresectable, Late-stage disease, Second-line therapy or greater) in China (SC, Injection)
  • 01 Apr 2023 Clinical trials in Solid tumours (Inoperable/Unresectable, Second-line therapy or greater, Late-stage disease) in China (SC) (NCT05749627)
  • 03 Mar 2023 Shenzhen Dengding Biopharma in collaboration with The First Affiliated Hospital of Nanchang University plans a clinical trial for Solid tumours (Inoperable/Unresectable, Second-line therapy, Late-stage disease) in China in April 2023 (SC) (NCT05749627)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top